Clinicians balance symptoms, MRI changes and family goals when deciding treatment for pediatric low-grade glioma, beyond size criteria

In a recent discussion, pediatric neuro‑oncology experts examined how they apply the RAPNO criteria to assess low‑grade gliomas in children. They highlighted that treatment decisions often go beyond simple tumor size measurements.

The physicians noted that the RAPNO framework is rarely mentioned directly to families. Instead, they rely on the child's overall condition, symptom profile and MRI findings to gauge whether therapy is needed.

Because many pediatric low‑grade gliomas do not enhance with contrast, the team cautioned that contrast uptake is an unreliable marker. They emphasized careful interpretation of MRI changes alongside clinical signs.

The conversation underscored a gap between guideline recommendations and real‑world practice, with clinicians tailoring decisions to individual patient circumstances and family priorities.